# FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

> **NCT03841110** · PHASE1 · COMPLETED · sponsor: **Fate Therapeutics** · enrollment: 37 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma
- Gastric Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma
- EGFR Positive Solid Tumor
- HER2-positive Breast Cancer
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- Pancreas Cancer
- Melanoma
- NSCLC
- Urothelial Carcinoma
- Cervical Cancer
- Microsatellite Instability
- Merkel Cell Carcinoma

## Interventions

- **DRUG:** FT500
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Atezolizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT03841110
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841110, "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03841110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*